S&P 500   0.63 (+2.44%)
DOW   0.63 (+2.44%)
BA   187.94 (+4.43%)
S&P 500   0.63 (+2.44%)
DOW   0.63 (+2.44%)
BA   187.94 (+4.43%)
S&P 500   0.63 (+2.44%)
DOW   0.63 (+2.44%)
BA   187.94 (+4.43%)
S&P 500   0.63 (+2.44%)
DOW   0.63 (+2.44%)
BA   187.94 (+4.43%)
Log in

NASDAQ:CLBSCaladrius Biosciences Stock Price, Forecast & News

$3.00
+0.84 (+38.89 %)
(As of 07/15/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.22
Now: $3.00
$3.21
50-Day Range
$1.74
MA: $1.88
$3.00
52-Week Range
$1.05
Now: $3.00
$3.64
Volume6.56 million shs
Average Volume309,038 shs
Market Capitalization$46.66 million
P/E RatioN/A
Dividend YieldN/A
Beta1.47
Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Its product pipeline includes CLBS12, CLBS14, and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ.
Read More
Caladrius Biosciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.34 out of 5 stars


Industry, Sector and Symbol

Industry Miscellaneous health & allied services, not elsewhere classified
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CLBS
CUSIPN/A
Phone908-842-0100

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.98 per share

Profitability

Net Income$-19,360,000.00

Miscellaneous

EmployeesN/A
Market Cap$46.66 million
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive CLBS News and Ratings via Email

Sign-up to receive the latest news and ratings for CLBS and its competitors with MarketBeat's FREE daily newsletter.

Caladrius Biosciences (NASDAQ:CLBS) Frequently Asked Questions

How has Caladrius Biosciences' stock been impacted by COVID-19 (Coronavirus)?

Caladrius Biosciences' stock was trading at $2.24 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CLBS shares have increased by 33.9% and is now trading at $3.00. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Caladrius Biosciences?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Caladrius Biosciences in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Caladrius Biosciences.

When is Caladrius Biosciences' next earnings date?

Caladrius Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Caladrius Biosciences.

How were Caladrius Biosciences' earnings last quarter?

Caladrius Biosciences Inc (NASDAQ:CLBS) posted its quarterly earnings data on Thursday, May, 7th. The biotechnology company reported ($0.38) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.29) by $0.09. View Caladrius Biosciences' earnings history.

What price target have analysts set for CLBS?

4 Wall Street analysts have issued 12-month price objectives for Caladrius Biosciences' shares. Their forecasts range from $6.00 to $18.50. On average, they expect Caladrius Biosciences' share price to reach $10.50 in the next year. This suggests a possible upside of 250.0% from the stock's current price. View analysts' price targets for Caladrius Biosciences.

Has Caladrius Biosciences been receiving favorable news coverage?

News headlines about CLBS stock have trended extremely negative this week, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Caladrius Biosciences earned a daily sentiment score of -4.3 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 3.0 out of 10, meaning that recent press coverage is unlikely to have an effect on the stock's share price in the near future. View the latest news about Caladrius Biosciences.

Who are some of Caladrius Biosciences' key competitors?

What other stocks do shareholders of Caladrius Biosciences own?

Who are Caladrius Biosciences' key executives?

Caladrius Biosciences' management team includes the following people:
  • David J. Mazzo, President, Chief Executive Officer & Director
  • Joseph Talamo, CFO, Principal Accounting Officer & Senior VP
  • Douglas W. Losordo, Chief Medical Officer & Executive Vice President
  • Greg Berkin, Vice President-Information Technology
  • John D. Menditto, VP-Investor Relations & Corporate Communications

What is Caladrius Biosciences' stock symbol?

Caladrius Biosciences trades on the NASDAQ under the ticker symbol "CLBS."

How do I buy shares of Caladrius Biosciences?

Shares of CLBS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Caladrius Biosciences' stock price today?

One share of CLBS stock can currently be purchased for approximately $3.00.

How big of a company is Caladrius Biosciences?

Caladrius Biosciences has a market capitalization of $46.66 million. The biotechnology company earns $-19,360,000.00 in net income (profit) each year or ($1.88) on an earnings per share basis.

What is Caladrius Biosciences' official website?

The official website for Caladrius Biosciences is www.caladrius.com.

How can I contact Caladrius Biosciences?

Caladrius Biosciences' mailing address is 110 ALLEN ROAD 2ND FLOOR, BASKING RIDGE NJ, 07920. The biotechnology company can be reached via phone at 908-842-0100 or via email at [email protected]

This page was last updated on 7/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.